Altria Group news

Altria maintains strong U.S. market dominance with 45.5% cigarette retail share and 64.8% smokeable margins, but faces headwinds from declining domestic cigarette volumes (-3.2%), slower projected earnings growth (4.6%), and limited smoke-free product penetration. The company is investing in newer formats but momentum is tempered.

Altria is presented favorably as a Dividend King with a strong 61-year history of consecutive dividend increases, demonstrating financial stability and commitment to shareholders. The article projects attractive dividend income potential ($7,430-$10,160 over 10 years) and highlights the company's targeted mid-single-digit dividend growth through 2028, supporting a positive investment thesis for income-focused investors.

While Altria demonstrated positive near-term price momentum (up 2.4% on the day and 4.99% over the month) and trades at a valuation discount, the Zacks Rank #3 (Hold) rating and stagnant EPS estimates over the past month suggest limited upside catalysts. The tobacco industry ranks in the bottom 9% of all industries, indicating structural headwinds that offset the company's relative outperformance.

Altria demonstrates strong dividend credentials with a 57-year streak and recent 4.7% increase, supported by a 6.15% yield. However, the company faces operational headwinds including declining shipment volumes in both smokeable (-2.7%) and oral tobacco (-6%) products, and concerning cash flow dynamics where dividends paid ($3.6B) exceeded free cash flow ($2.9B) in H1 2026. The stock warrants cautious monitoring rather than outright bullish or bearish positioning.

Mixed signals: strong profitability growth (OCI +2.4%) and pricing power support the company, but declining overall market share (-1.5 points) and increased consumer trade-down to discounts present headwinds. The company's defensive strategy shows resilience but faces structural market challenges.

While on! PLUS shows positive early traction with broad retail reach and encouraging repeat purchase rates, the company faces significant competitive headwinds from well-funded competitors. Stock underperformance and modest earnings growth forecasts (3-4.6% YoY) temper the positive product momentum.

Declining demand for core tobacco products, revenue growth driven by price increases rather than volume growth (volume fell 2.7%), unsustainable long-term business model, and reliance on price hikes to maintain dividend growth despite falling volumes.

Stock declined 9.3% on Q2 earnings miss, with EPS falling short of estimates by $0.02. Persistent volume declines in cigarette shipments (-4.5% YoY) and guidance midpoint below analyst expectations indicate weakening business fundamentals and investor confidence.

Recommended as the better buy in 2026 due to excellent dividend payments (5.82% yield), lower forward P/E ratio (13.0x), strong free cash flow ($9.1B), and high profitability despite declining traditional cigarette volumes. Management is successfully boosting profits with net income expected to rise 25% in 2026.

Strong domestic market dominance, excellent dividend yield (5.83%), lower valuation multiple (P/E 15.2x), and high profitability ($6.95B net income). However, sentiment is tempered by declining U.S. smoking rates, sluggish revenue growth expectations (5% over 5 years), and legal/regulatory headwinds including antitrust lawsuits and e-cigarette import bans.

Core cigarette business experiencing significant decline (10% volume drop in 2025), failed diversification attempts resulting in billions in write-offs, and high dividend yield reflects underlying business risk despite Dividend King status.

Core cigarette business declining 10% annually with unsustainable price-hike strategy. Diversification efforts have mostly failed. On! product faces stiff competition and lost market share in Q4. Long-term profitability at risk if smoke-free products don't succeed.

While the nationwide expansion of nicotine pouches is a positive strategic move and the company offers an attractive 6.7% dividend yield with a 56-year track record of increases, the article emphasizes limited net growth potential. Oral nicotine pouches are primarily cannibalizing existing oral tobacco sales rather than converting new smokers, and online availability already exists in most states, limiting the impact of brick-and-mortar expansion. The company is managing decline well but not achieving meaningful growth.

Stock gained 2.82% today and is up 15% year-to-date. Benefiting from investor rotation into defensive dividend stocks due to market uncertainty. Company expanding On! Plus product nationally, which could drive market share gains in the growing oral nicotine pouch segment.

Attractive valuation at 12x forward earnings, high dividend yield (6.5%), strong EPS growth expected at 13% CAGR through 2028, strategic diversification into smoke-free products targeting $5 billion revenue by 2028, and effective cost management with share buybacks.

Highest yield at 6.4% with 61 consecutive years of dividend increases and 4.7% recent raise. Strong pricing power offsets volume declines. However, carries the most long-term business risk due to declining cigarette shipments and dependence on smoke-free product transition.

While Altria has delivered strong 2026 performance (24% returns) and maintains an attractive 6.4% dividend yield at a cheap valuation, the article highlights significant long-term risks. Slowing revenue growth (1.2%), declining earnings, and the company's struggle to compete in smokeless products compared to Philip Morris International suggest the stock could become a yield-and-value trap if earnings growth falters.

Despite 6.4% yield, stock appears expensive with P/S and P/E ratios above five-year averages. Fundamental headwind of declining cigarette volumes (Marlboro down 7.6% YoY) suggests business is in structural decline. High yield may not be sustainable long-term.

Dividend King status with 50+ consecutive annual dividend increases, manageable 74% payout ratio, diversified product portfolio, and 5.9% yield trading at under 13x forward earnings provide strong income potential despite low-single-digit earnings growth.

Maintains Dividend King status with 57 consecutive years of dividend increases. Company is adapting to declining cigarette demand through price increases, cost reduction plans, and expansion into non-tobacco nicotine pouches. Forward yield of nearly 6% supports dividend sustainability.

Recommended for its recession-proof tobacco business, highest yield at 5.82%, ability to raise prices to offset volume declines, and strong cash flow supporting the 81% payout ratio. Multi-billion dollar stake in Anheuser-Busch InBev provides additional financial flexibility.

Dividend King with 50+ years uninterrupted increases; pivoting to high-growth smokeless products expanding 25% annually; strong pricing power; sure dividend hike expected late August

56 consecutive years of dividend increases despite declining volumes, strong pricing power from addictive product, manageable payout ratio, and robust 5.9% dividend yield make it a reliable long-term holding.

Mentioned only as context for Philip Morris International's 2008 spinoff; no investment recommendation provided.

Mentioned only as the former parent company of Philip Morris International; not evaluated as an investment recommendation.

Dividend King with 60 dividend increases over 56 years; diversifying into smoke-free products targeting $5 billion revenue by 2028; highest yield among the four at 6.47%; strong pricing power and cost management.

Strong dividend yield (6.3%) and reliable cash flows supported by price-insensitive smokers, but offset by declining cigarette demand in North America and past billion-dollar write-offs from product diversification attempts. Suitable only for aggressive investors.

Altria presents a mixed investment case. Positive factors include strong dividend history (57 consecutive years of increases), high yield (6.27%), solid cash flow, and recession-resistant business. However, significant concerns exist regarding declining smoking volumes, failed investments (Juul loss of $13B), and inability to compete effectively in smoke-free categories like nicotine pouches. The stock is suitable for income-focused investors but carries long-term structural risks.

Highlighted as a Dividend King with 50+ years of consecutive dividend increases, representing 4.08% of SCHD holdings.

Mentioned as a holding within the SCHD ETF portfolio but no specific analysis or commentary is provided about the company itself.

Top holding in SCHD with blue-chip status and long dividend history; consumer staples sector provides stability and diversification from technology.

Positioned as a reliable dividend stock with a 6.13% yield, Dividend King status with 56 consecutive annual increases, and a sustainable payout ratio of 75% of earnings. However, concerns about declining cigarette volumes and dependence on price increases temper enthusiasm.

Generates substantial cash flow from established tobacco business with 45.2% market share, maintains a strong 6.1% dividend yield, supports shareholder returns through buybacks, and has financial strength to invest in new growth platforms despite core business decline.

Altria is mentioned as the U.S.-focused counterpart to PMI following their 2008 spin-off. While not the focus of the recommendation, it maintains the Marlboro brand alongside PMI but lacks the international diversification and smoke-free product growth that makes PMI more attractive.